| Title |
Myxedema Psychosis: Systematic Review and Pooled Analysis
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, August 2021
|
| DOI | 10.2147/ndt.s318651 |
| Pubmed ID | |
| Authors |
Mouhand F H Mohamed, Mohammed Danjuma, Mohammed Mohammed, Samreen Mohamed, Martin Siepmann, Kristian Barlinn, Salah Suwileh, Lina Abdalla, Dabia Al-Mohanadi, Juan Carlos Silva Godínez, Abdel-Naser Elzouki, Timo Siepmann |
| Abstract |
The term myxedema psychosis (MP) was introduced to describe the occurrence of psychotic symptoms in patients with untreated hypothyroidism, but the optimal assessment and treatment of this condition are unclear. We aimed to synthesize data from the literature to characterize the clinical presentation and management of MP. We performed a systematic review according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines in PubMed (Medline), Embase, Google Scholar, and Cochrane databases, including observational studies, case series, and case reports published from 1/1/1980 to 31/12/2019 in the English language. Descriptive statistics along with univariate and multivariate analysis were used for data synthesis. Out of 1583 articles screened, 71 case reports met our inclusion criteria providing data on 75 MP cases. The median age at diagnosis was 42 years [32-56]. About 53% had no prior hypothyroidism diagnosis. Delusions occurred in 91%, with a predominance of persecutory ideas (84%), while hallucinations occurred in 78%. Physical symptoms and signs of hypothyroidism were absent in 37% and 26%, respectively. If symptoms occurred, nonspecific fatigue was seen most frequently (63%). The median thyroid-stimulating hormone value was 93 mIU/L [60-139]. Thyroid peroxidase antibodies were found positive in 75% (23/33) of reported cases. Creatinine kinase was reported abnormal in seven cases. Cranial imaging (CT or MRI) and electroencephalogram were normal in 89%, 75%, and 73% of the cases reported. The majority of patients were treated orally with thyroxine in combination with short-term antipsychotics. More than 90% of them showed complete recovery. Univariate analysis revealed a trend towards a shorter duration of psychosis with IV thyroid hormone therapy (p= 0.0502), but the effect was not consistent in a multivariate analysis. While we identified a substantial lack of published research on MP, our pooled analysis of case observations suggests that the condition presents a broad spectrum of psychiatric and physical symptoms lending support to the value of screening for thyroid dysfunction in patients with first-ever psychosis. CRD42020160310. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| Germany | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Researcher | 3 | 11% |
| Student > Doctoral Student | 2 | 7% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 14 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 21% |
| Nursing and Health Professions | 3 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Arts and Humanities | 1 | 4% |
| Neuroscience | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 14 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2023.
All research outputs
#7,966,302
of 25,392,582 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,036
of 3,131 outputs
Outputs of similar age
#154,746
of 436,332 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#12
of 33 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.